Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients

Akihiro Tamiya; Kentaro Yamazaki; Narikazu Boku; Nozomu Machida; Takashi Kojima; Keisei Taku; Hirofumi Yasui; Akira Fukutomi; Shuichi Hironaka; Yusuke Onozawa

首页> 外文期刊>International Journal of Clinical Oncology >Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients

【24h】

Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients

机译：贝伐单抗联合标准化疗治疗转移性结直肠癌的安全性：65例日本患者的回顾性回顾

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Bevacizumab (BV) prolongs overall survival and progression-free survival when combined with standard chemotherapy for metastatic colorectal cancer (mCRC). However, because this drug was approved in Japan only in 2007, there has been little experience in Japan. This study was conducted to evaluate retrospectively the safety of BV in clinical practice.

机译：当与标准化疗联合用于转移性结直肠癌（mCRC）时，贝伐单抗（BV）可延长总体生存期和无进展生存期。但是，由于该药仅在2007年才在日本获得批准，因此在日本几乎没有经验。进行这项研究以回顾性评估BV在临床实践中的安全性。

著录项

来源
《International Journal of Clinical Oncology》 |2009年第6期|513-517|共5页
作者
Akihiro Tamiya; Kentaro Yamazaki; Narikazu Boku; Nozomu Machida; Takashi Kojima; Keisei Taku; Hirofumi Yasui; Akira Fukutomi; Shuichi Hironaka; Yusuke Onozawa;
展开▼
作者单位

Division of Thoracic Oncology Shizuoka Cancer Center Shizuoka Japan;

Division of Gastrointestinal Oncology Shizuoka Cancer Center 1007 Shimonagakubo Nagaizumi-cho Shizuoka 411-8777 Japan;

Division of Gastrointestinal Oncology Shizuoka Cancer Center 1007 Shimonagakubo Nagaizumi-cho Shizuoka 411-8777 Japan;

Division of Gastrointestinal Oncology Shizuoka Cancer Center 1007 Shimonagakubo Nagaizumi-cho Shizuoka 411-8777 Japan;

Division of Gastrointestinal Oncology Shizuoka Cancer Center 1007 Shimonagakubo Nagaizumi-cho Shizuoka 411-8777 Japan;

Division of Gastrointestinal Oncology Shizuoka Cancer Center 1007 Shimonagakubo Nagaizumi-cho Shizuoka 411-8777 Japan;

Division of Gastrointestinal Oncology Shizuoka Cancer Center 1007 Shimonagakubo Nagaizumi-cho Shizuoka 411-8777 Japan;

Division of Gastrointestinal Oncology Shizuoka Cancer Center 1007 Shimonagakubo Nagaizumi-cho Shizuoka 411-8777 Japan;

Division of Gastrointestinal Oncology Shizuoka Cancer Center 1007 Shimonagakubo Nagaizumi-cho Shizuoka 411-8777 Japan;

Division of Gastrointestinal Oncology Shizuoka Cancer Center 1007 Shimonagakubo Nagaizumi-cho Shizuoka 411-8777 Japan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
Bevacizumab; Safety; Colorectal cancer;

机译：贝伐单抗;安全性;结直肠癌;

相似文献

外文文献
中文文献
专利

1. Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients. [J] . Tamiya A, Yamazaki K, Boku International journal of clinical oncology . 2009,第6期

机译：贝伐单抗联合标准化疗治疗转移性结直肠癌的安全性：回顾性分析65例日本患者。
2. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No. 150 and part review of technology appraisal No. 118): a systematic review and economic model [J] . Health technology assessment: HTA . 2013,第14期

机译：一线化疗后西妥昔单抗（单药或联合化疗），贝伐单抗（与非奥沙利铂化疗联合）和帕尼单抗（单药）治疗转移性结直肠癌的临床疗效和成本效益（技术评估编号第150号技术评估和第118号技术评估的部分复审：系统复审和经济模型
3. Chemotherapy with bevacizumab for metastatic colorectal cancer: A retrospective review of 181 Japanese patients [J] . SaitoS., HayashiN., SatoN., International journal of clinical oncology . 2013,第4期

机译：贝伐单抗化学疗法治疗转移性结直肠癌：181例日本患者回顾性回顾
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy) bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model. [O] . M Hoyle, L Crathorne, J Peters, -1

机译：一线化疗后西妥昔单抗（单药或联合化疗）贝伐单抗（与非奥沙利铂化疗联合）和帕尼单抗（单药）治疗转移性结直肠癌的临床疗效和成本效益（技术评估编号第150号技术评估书和第118号技术评估书的一部分复审：系统的复审和经济模型。
7. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model [O] . Hoyle, M, Crathorne, Louise, Peters, J, 2013

机译：一线化疗后西妥昔单抗（单药或联合化疗），贝伐单抗（与非奥沙利铂化疗联合）和帕尼单抗（单药）治疗转移性结直肠癌的临床疗效和成本效益（技术评估编号第150号技术评估和第118号技术评估的部分复审：系统复审和经济模型

Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients

摘要

著录项

相似文献

相关主题

期刊订阅